An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Reduction of total liver volume after 6 months of treatment measured by means of CT-scan.
Reduction of total liver volume after 6 months measured by means of CT-scan.
Frederik Nevens, MD, PhD
UZ Leuven, Gasthuisberg
Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment